MedWire News: Adding ezetimibe to atorvastatin therapy in patients at moderately high risk (MHR) and high risk (HR) for coronary heart disease (CHD) is more likely to achieve treatment targets for hypercholesterolemia compared with doubling the atorvastatin dose, researchers have found.
